The North America generic drugs market size surpassed USD 142.60 billion in 2025 and is predicted to reach around USD 221.45 billion by 2035, registering a CAGR of 4.5% from 2026 to 2035. North America experiences the increased accessibility of generics to patients who require new medications, life-saving treatments, and essential therapies.

North America Generic Drugs Market Statical Scope

The major therapeutic areas driving opportunities in the generic drugs market are oncology , cardiology, diabetes, obesity, immunology , and monoclonal antibodies . Research suggests that oncology is the fastest-growing area, with an expected expiration of patent protection for immune-oncology drugs like Keytruda and Opdivo that will create huge opportunities for biosimilar developers. Moreover, there is a high global demand for generic and biosimilar manufacturers for diabetes and obesity care, which further drives their entry into the market. The stakeholders who aim to invest and expand in the generic drugs industry usually focus on understanding the regional variations related to generic drug opportunities in these therapeutic areas.

North America Generic Drugs Market Share, By Drug Type, 2025 (%)

• Simple Generics- The simple generics segment dominated the market in 2025, with a revenue share of 62%, owing to the widespread usage of simple generic medicines, which impose cost-effectiveness and high prescription volumes across common therapeutic areas.
• Biosimilars- The biosimilars segment held a share of 16% due to the huge adoption of cost-effective alternatives to biologics and patent expirations of branded drugs.

North America Generic Drugs Market Share, By Therapeutic Area, 2025 (%)

• Cardiovascular- The cardiovascular segment led the market in 2025 by holding a major revenue share of 24%, owing to the rising prevalence of heart-related conditions and consistent demand for long-term medications.
• Oncology- The oncology segment accounted for a share of 18%, driven by the increasing cancer prevalence and the growing use of generic cancer therapies.

North America Generic Drugs Market Share, By Route of Administration, 2025 (%)

• Oral Solids- The oral solids segment held a remarkable share of 55% in the market in 2025, owing to increased patient compliance, the ease of administration, and cost-effectiveness.
• Injectables- The injectables segment is growing in the market with a share of 20%, supported by the increased use of injectables in acute care, biologics, and hospital-based treatments.

North America Generic Drugs Market Share, By Distribution Channel, 2025 (%)

• Retail Pharmacies- The retail pharmacies segment occupied a dominating position in the market in 2025, and held a share of 52%, owing to the high volume of prescription dispensing and widespread accessibility of generics.
• Hospital Pharmacies- The hospital pharmacies segment is expanding in the market with a considerable share of 22%, because of the growing popularity of hospital pharmacies for acute care and inpatient treatments.

Top Companies in the North America Generic Drugs Market

• Sandoz
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC

Segments Covered in the Report

By Drug Type

• Simple Generics
• Specialty Generics
• Biosimilars
• Complex Generics

By Therapeutic Area

• Cardiovascular
• Oncology
• Anti-Infective
• Central Nervous System
• Endocrine/Metabolic
• Respiratory
• Others

By Route of Administration

• Oral
• Injectable
• Topical
• Inhalable
• Other Route of Administration

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channel